



LORAZEPAM 0.5mg Tablets

Product strength
addressing
a therapy gap

- **Indicated for** short term (2-4 weeks only) use (adults only)
 - Symptomatic relief of anxiety that is severe, disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness
 - As premedication (adults and children 5 years and above)
 - Before operative dentistry and general surgery

Available dossier
from Q4/2022

Available strength: 0.5mg

0.5mg is specially used in patients with renal or hepatic impairment

- Patients with impaired renal or hepatic function have recommendation of lower doses as per SmPC of Lorazepam

Reference markets

- Lorazepam continues to be one of the main therapies, with sales of 2.1b tablets (MAT Q2 2022) and growing, as per IQVIA (EU27+UK)

Regulatory pathway

- Legal basis: Article 10(3) hybrid application

Development status

- EU dossier available from Q4/2022

Partnership options

- Dossier for selected markets on exclusive or semi-exclusive base or license
- Dossier can be adjusted to markets outside Europe based on request

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.